/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

S

Soraia Lobo-Martins

Université Libre de Bruxelles(BE)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

32

Papers

108

Citations

5

h-index

2

i10-index

Soraia Lobo-Martins is an academic researcher from Université Libre de Bruxelles. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Cancer Immunotherapy and Biomarkers & Breast Cancer Treatment Studies. The author has an h-index of 5, co-authored 28 publications.

ORCID: 0000-0001-5847-7192

Research Topics

Advanced Breast Cancer Therapies Cancer Immunotherapy and Biomarkers Breast Cancer Treatment Studies HER2/EGFR in Cancer Research Colorectal Cancer Treatments and Studies

Papers by this author

works

Genetic and microenvironmental intra-tumor heterogeneity impacts colorectal cancer evolution and metastatic development

2022 · Communications Biology · 36 citations

https://doi.org/10.1038/s42003-022-03884-x

Daniel Sobral Marta Martins Shannon Kaplan Mahdi Golkaram

355P EVERolimus effectiveness after proGREssion on CDK4/6 inhibitors for ENdocrine receptor-positive/HER2-negative, advanced breast cancer: EVERGREEN quasi-experimental study

2024 · Annals of Oncology · 2 citations

https://doi.org/10.1016/j.annonc.2024.08.303

Soraia Lobo-Martins Diogo Martins-Branco Philippe Aftimos Brooke Pereira

Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge

2025 · ESMO Open · 2 citations

https://doi.org/10.1016/j.esmoop.2025.105758

R. Gerosa Gabriella Gentile Luca Arecco Chiara Dauccia

Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study

2025 · Clinical Breast Cancer · 1 citations

https://doi.org/10.1016/j.clbc.2025.05.002

Soraia Lobo-Martins Véronique Debien Elisa Agostinetto Marianna Sirico

The MELimmune score—prognostic factors for overall survival in advanced melanoma and anti-PD-1 monotherapy—a multicentre, retrospective cohort study

2025 · Immuno-Oncology Technology · 0 citations

https://doi.org/10.1016/j.iotech.2025.101043

Soraia Lobo-Martins Diogo Martins-Branco P. Semedo Cecilia Melo Alvim

685P Systemic efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with central nervous system (CNS) metastases (mets) from solid tumors: A systematic review and meta-analysis

2025 · Annals of Oncology · 0 citations

https://doi.org/10.1016/j.annonc.2025.08.1260

Soraia Lobo-Martins Diogo Martins-Branco Carmen Lara Maria Grazia Bruzzone

Research topics

topics

Advanced Breast Cancer Therapies

Cancer Immunotherapy and Biomarkers

Breast Cancer Treatment Studies

HER2/EGFR in Cancer Research

Colorectal Cancer Treatments and Studies

Chat about Author

Papers

Chat

Click to start Chat